Noninvasive and Multiplex Self-Test of Kidney Disease Biomarkers with Graphene-Based Lab-on-a-Chip (G-LOC): Toward Digital Diagnostics in the Hands of Patients
Diforti et al.
The finding, in our words
A graphene lab-on-a-chip device achieved high accuracy and precision for multiplex renal biomarker testing in serum and saliva, with sensitivities ranging from 89.0 to 99.7 per cent. Untrained volunteers produced results comparable to trained chemists, suggesting the device is suitable for patient-centric at-home diagnostics and could improve access to chronic kidney disease monitoring.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.
A 2025 review maps 28 microsampling devices, from dried spots and volumetric absorptive tips to upper-arm liquid capillary collectors, and names what a laboratory must control before their results are used: the haematocrit effect in non-volumetric dried samples, interstitial fluid from finger milking, volume, haemolysis and transport stability. Regulators on both sides of the Atlantic ask for the same two things, a device the patient can use safely and a sample fit for the test.
This systematic review of 67 studies involving 34,739 kidney disease patients found dried blood microsampling was mainly used for immunosuppressant therapeutic drug monitoring and kidney function assessment. The approach offered cost savings, was preferred by patients for home self-collection, and provides a patient-centric opportunity to upscale longitudinal sampling and reduce participation bias in decentralised kidney disease research.
Lamond et al., Journal of clinical laboratory analysis · source ↗
An IQ Consortium position paper from sponsor scientists positioning patient-centric sampling as the enabling technology for decentralised trials, and stating that a bridging study against conventional sampling “has quickly been established as a regulatory expectation”.
Maass et al., Clinical and Translational Science · source ↗
Capillary blood self-sampling achieved 98.3% agreement with venous samples for SARS-CoV-2 IgG antibodies and 100% for IgA among 60 participants, demonstrating accuracy for vaccine monitoring. Saliva self-collection proved feasible with excellent usability, offering a patient-centric alternative for decentralised immunogenicity assessment.
Schmetzer et al., Frontiers in public health · source ↗